DDInter624 DDInter1925
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Efavirenz {u} (Compound) downregulates {v} (Gene) PFN1
PFN1 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Efavirenz {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Efavirenz {u} (Compound) downregulates {v} (Gene) PFN1
PFN1 {u} (Gene) is regulated by {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Vemurafenib
Efavirenz {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) regulates {v} (Gene) CRIP1
CRIP1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Efavirenz {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Efavirenz {u} (Compound) causes {v} (Side Effect) Myalgia
Myalgia {u} (Side Effect) is caused by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vemurafenib
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Vemurafenib (Compound)
Efavirenz (Compound) downregulates PFN1 (Gene) and PFN1 (Gene) is downregulated by Vemurafenib (Compound)
Efavirenz (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Efavirenz (Compound) downregulates PFN1 (Gene) and PFN1 (Gene) is regulated by ALB (Gene) and ALB (Gene) is bound by Vemurafenib (Compound)
Efavirenz (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) regulates CRIP1 (Gene) and CRIP1 (Gene) is upregulated by Vemurafenib (Compound)
Efavirenz (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Efavirenz (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Vemurafenib